Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-intensified CHOP versus rituximab high-dose sequential therapy with autologous stem cell transplantation in high-risk DLBCL
NL-OMON20455Phase 3Recruiting
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 6 more in diffuse large B-cell lymphoma (DLBCL) (2 arms). Primary endpoint: Event-free survival. Started Oct 2005; status: recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON20455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20455.